Molnupiravir lowers long COVID risk: study
Antiviral still has a role to play despite guidelines advising against routine use for mild disease, says Associate Professor Paul Griffin.
Molnupiravir may cut the risk of long COVID symptoms as well as post-acute death, regardless of a patient’s vaccination status or prior infection, US epidemiologists report.
Their study of nearly 230,000 veterans with COVID-19 suggests the antiviral is associated with a 14% lower relative risk of post-acute sequalae versus no treatment.
It was also linked to a 38% and 14% reduced risk of post-acute death and hospital admission, respectively.
In absolute terms, the risk reduction at 180 days was between 0.9% and 3% across the three main outcomes, the researchers said.
